Getting diagnosed with Alzheimer’s involves a series of steps that typically starts with your primary care doctor and ends with a specialist confirming the diagnosis through cognitive testing, brain imaging, and increasingly, blood or spinal fluid biomarkers. The full process from first reporting symptoms to receiving a diagnosis often takes anywhere from a few months to over a year, depending on how quickly you’re referred to a specialist and which tests are needed.
There is no single test that confirms Alzheimer’s on its own. Instead, doctors piece together results from cognitive exams, lab work, imaging, and biomarker tests while ruling out other treatable conditions that can mimic dementia. Here’s what that process looks like in practice.
The First Appointment and What to Expect
Most people start by seeing their primary care physician. About 79% of patients first bring their concerns to a family doctor or general practitioner rather than going directly to a specialist. At this visit, your doctor will ask about the specific memory or thinking problems you’ve noticed, when they started, and whether they’ve gotten worse over time. They’ll also review your medications, since some drugs can cause or worsen cognitive problems, and ask about your mood, sleep, and alcohol use.
Your doctor will likely order basic blood work at this stage. This isn’t to test for Alzheimer’s directly. It’s to check for conditions that cause reversible memory problems: low vitamin B12, an underactive thyroid, untreated sleep disorders like obstructive sleep apnea, or metabolic imbalances. Depression is another common cause of cognitive difficulties that needs to be identified or ruled out early. If any of these turn up, treating them may improve your thinking without further workup.
From this first consultation, one of two things happens. Your primary care doctor may feel confident making the diagnosis themselves (about 17% of diagnoses happen this way), or they’ll refer you to a neurologist, geriatrician, or geriatric psychiatrist for further evaluation. If you’re referred, expect the time from that initial visit to diagnosis to stretch to roughly 29 weeks on average, though it can be shorter or longer depending on wait times and how many tests are needed.
Cognitive Testing
A key part of the diagnostic process is a standardized cognitive screening test, usually done in the office during a short appointment. The most widely used tools are the Montreal Cognitive Assessment (MoCA), the Mini-Mental State Examination (MMSE), and the Mini-Cog. These tests evaluate memory, attention, language, and spatial reasoning through tasks like drawing a clock face, recalling a short list of words, or naming animals.
On the MoCA, a score below 26 (out of 30) is the standard threshold for mild cognitive impairment, and a score around 18 or below raises concern for Alzheimer’s specifically. The MMSE uses various threshold scores depending on the clinical context, and there’s no single universally agreed-upon cutoff. These screenings don’t diagnose Alzheimer’s by themselves, but they quantify how much your thinking has changed and help track whether it worsens over time.
Some specialists also use more detailed neuropsychological testing, which can take several hours and evaluates specific types of memory, problem-solving, and language skills in greater depth. This longer testing is especially helpful when symptoms are mild or when the pattern of difficulties doesn’t clearly point to one diagnosis.
Ruling Out Other Causes
Before confirming Alzheimer’s, doctors need to eliminate conditions that look similar but have different treatments. Beyond the basic blood work mentioned earlier, this can include checking for normal pressure hydrocephalus, a condition where fluid builds up in the brain and causes memory loss, difficulty walking, and bladder control problems. Unlike Alzheimer’s, this can sometimes be treated with surgery.
Brain imaging with an MRI or CT scan is standard at this stage. These scans look for structural problems like brain tumors, previous strokes, or fluid buildup. They also show patterns of brain shrinkage that may suggest Alzheimer’s or another type of dementia. In certain cases, doctors may test for autoimmune encephalitis (where the immune system attacks the brain, causing rapid cognitive decline) or infections like syphilis in patients with relevant risk factors. Excessive alcohol use is another consideration, since it can lead to a specific type of brain damage through thiamine deficiency.
Biomarker Tests That Confirm the Disease
The 2024 revised diagnostic criteria from the National Institute on Aging and the Alzheimer’s Association established that Alzheimer’s is defined biologically, not just by symptoms. This means confirming that the hallmark brain changes (buildup of amyloid plaques and tau tangles) are actually present, using one or more biomarker tests.
There are three main ways to detect these changes:
- Blood tests: A newer and less invasive option. Blood tests measuring a protein called p-tau217 have shown roughly 90% accuracy at identifying Alzheimer’s-related brain changes, performing about as well as spinal fluid analysis and brain imaging. These tests are becoming more widely available but are not yet standard everywhere.
- Spinal fluid analysis: A lumbar puncture (spinal tap) collects a small sample of the fluid surrounding your brain and spinal cord. Doctors measure ratios of amyloid and tau proteins in this fluid. Specific shifts in these ratios, particularly a drop in one type of amyloid protein relative to another and a rise in phosphorylated tau, indicate Alzheimer’s pathology.
- PET brain scans: Amyloid PET and tau PET scans use small amounts of a radioactive tracer injected into a vein that binds to plaques or tangles in the brain, making them visible on imaging. Results are measured on a standardized scale where 0 represents a healthy young brain and 100 represents typical Alzheimer’s-level deposits. Scans registering between 10 and 40 on this scale may be considered positive depending on the clinical context, with lower thresholds used to catch earlier-stage disease.
Not every patient receives all three types of biomarker testing. Your doctor will choose based on availability, insurance coverage, and how much diagnostic certainty is needed. PET scans are expensive and not available in all areas. Blood tests are rapidly expanding access, but spinal fluid testing remains the most established lab-based method in many clinical settings.
What About Genetic Testing?
You may have heard about the APOE-e4 gene, which increases the risk of developing Alzheimer’s. Testing for this gene is voluntary and is not required for diagnosis. Carrying the gene doesn’t mean you will develop the disease, and not carrying it doesn’t mean you won’t. It’s a risk factor, not a diagnostic marker.
That said, if you’ve already been diagnosed, your doctor may suggest APOE testing to help guide treatment decisions. Some of the newer Alzheimer’s therapies carry different risk profiles depending on your APOE status, so knowing your genotype can influence which medications your doctor recommends.
How Long the Full Process Takes
The timeline varies significantly. People typically wait about five months from the time symptoms start before seeing a doctor at all. If your primary care physician diagnoses you directly, the process from first appointment to diagnosis takes a median of about 13 weeks. If you’re referred to a specialist, that stretches to closer to 29 weeks, and sometimes beyond a year.
Neurologists handle the diagnosis in the majority of cases and initiate treatment about 73% of the time. Geriatricians and geriatric psychiatrists make up most of the remaining specialist diagnoses. The process can feel slow, but each step serves a purpose: confirming that the cognitive decline is real, making sure it’s not caused by something treatable, and identifying the specific type of dementia so treatment can be targeted appropriately.
What a Diagnosis Actually Means Now
Under the 2024 criteria, Alzheimer’s is understood as a continuum. Brain changes begin years before noticeable symptoms, then progress through stages of increasing severity. Biomarker testing can now detect the disease at very early stages, but the current guidelines only support using these tools in people who already have symptoms. Testing asymptomatic individuals for Alzheimer’s biomarkers is still considered a research activity, not standard clinical care, partly because disease-targeted therapies haven’t been approved for people without symptoms.
If your results confirm Alzheimer’s, your doctor will stage the disease based on how much brain change is present and how severe your symptoms are. This staging helps determine whether you’re a candidate for newer therapies that target amyloid buildup and sets a baseline for tracking progression over time.